Skip to main content
. 2024 Feb 28;13(2):321–333. doi: 10.21037/tlcr-23-804

Figure 3.

Figure 3

Kaplan-Meier survival plots of 5-year overall survival in ALK-positive non-small cell lung cancer patients treated with second- or third-generation ALK inhibitors. The log-rank tests compared high and low expression levels of c-MET (A), EGFR (B), and HER3 (C) in primary tumors and those of c-MET (D), EGFR (E), HER2 (F), and HER3 (G) in secondary tumors. In the variant 1/2 subgroup, log-rank tests compared high and low expression levels of EGFR (H) and HER3 (I) in primary tumors and those of c-MET (J), EGFR (K), HER2 (L), and HER3 (M) in secondary tumors. ALK, anaplastic lymphoma kinase.